On Invalid Date, Elicio Therapeutics (NASDAQ: ELTX) reported Q2 2023 earnings per share (EPS) of -$2.44, up 5.17% year over year. Total Elicio Therapeutics earnings for the quarter were -$7.56 million. In the same quarter last year, Elicio Therapeutics's earnings per share (EPS) was -$2.32.
As of Q4 2023, Elicio Therapeutics's earnings has grown year over year. Elicio Therapeutics's earnings in the past year totalled -$27.52 million.
What is ELTX's earnings date?
Elicio Therapeutics's earnings date is Invalid Date. Add ELTX to your watchlist to be reminded of ELTX's next earnings announcement.
What was ELTX's revenue last quarter?
On Invalid Date, Elicio Therapeutics (NASDAQ: ELTX) reported Q2 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Elicio Therapeutics's revenue was $0.00.
What was ELTX's revenue growth in the past year?
As of Q4 2023, Elicio Therapeutics's revenue has grown -100% year over year. This is 199.5 percentage points lower than the US Biotechnology industry revenue growth rate of 99.5%. Elicio Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.